{{Rsnum
|rsid=1143663
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Chromosome=21
|Orientation=plus
|Gene=CBR1
|position=36070377
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|Gene_s=CBR1,LOC100133286
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 0.0 | 0.9 | 99.1
| HCB | 0.0 | 0.7 | 99.3
| JPT | 0.0 | 0.0 | 100.0
| YRI | 0.0 | 0.0 | 100.0
| ASW | 0.0 | 0.0 | 0.0
| CHB | 0.0 | 0.7 | 99.3
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.9 | 99.1
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs1143663
|Name_s=CBR1:Val88Ile; V88I
|Gene_s=CBR1, SETD4
|Feature=
|Evidence=PubMed ID:19204081
|Annotation=Risk or phenotype-associated allele: A Phenotype: Kinetic studies using purified, histidine-tagged, recombinant enzymes demonstrated that the V88I mutation leads to a significantly reduced maximal rate of activity for doxorubicin and daunorubicin compared to wild type protein. Type of association: FA
|Drugs=daunorubicin; doxorubicin
|Drug Classes=ANTHRACYCLINES AND RELATED SUBSTANCES
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165291529
}}

{{PMID Auto
|PMID=17344335
|Title=A functional genetic polymorphism on human carbonyl reductase 1 (CBR1 V88I) impacts on catalytic activity and NADPH binding affinity.
|OA=1
}}

{{PMID Auto
|PMID=19022938
|Title=Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donors.
|OA=1
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}